Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Prescient Therapeutics Limited ( (AU:PTX) ) has shared an announcement.
Prescient Therapeutics has announced a Share Purchase Plan (SPP) aiming to raise $7 million to fund the Phase 2 clinical development of its cancer therapy, PTX-100. This initiative reflects the company’s commitment to progressing its innovative treatment towards regulatory approval, potentially enhancing its market position and offering new hope for patients with unmet medical needs.
More about Prescient Therapeutics Limited
Prescient Therapeutics is an ASX-listed biotechnology company focused on developing targeted and personalized cancer treatments. The company is dedicated to advancing therapies that address significant unmet medical needs in the oncology sector.
Average Trading Volume: 859,643
Technical Sentiment Signal: Sell
Current Market Cap: A$37.04M
For an in-depth examination of PTX stock, go to TipRanks’ Overview page.